BILL ANALYSIS

S1973

BULLISH

Treat and Reduce Obesity Act of 2025

S1973 (Treat and Reduce Obesity Act of 2025) has been assessed with a bullish outlook for investors. This legislation directly affects Eli Lilly ($LLY) and $NVO. The primary sectors impacted are Healthcare and Consumer. View the full bill text on Congress.gov.

bullish

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

S.1973 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking 27M Medicare beneficiaries as new patients

$NVO (Wegovy) and $LLY (Zepbound) are the two direct beneficiaries with obesity-specific drug franchises

Bill is early-stage (referred to committee, no hearings yet); bipartisan support but uncertain path to law

Real market data shows $NVO +15.56% vs $LLY +0.7% over 30 days, suggesting market pricing in a Novo premium on Medicare exposure

No companion bill has passed either chamber; attaching to year-end must-pass legislation is the most likely path to enactment

How S1973 Affects the Market

The divergence in recent price action between $NVO (+15.56% in 30 days) and $LLY (+0.7%) presents a potential rotational opportunity if the market is underestimating LLY's exposure. Both companies have FDA-approved obesity drugs; the Medicare expansion is neutral in terms of net benefit per patient. The risk is that the bill stalls — early-stage legislation with 22 cosponsors has roughly a 10-20% historical passage rate. If investors seek a pure-play bet on Medicare expansion, $NVO at $42.47 is already pricing in some success. $LLY at $926.25 is 18% off its 52-week high of $1,133.95, offering more upside if the bill gains momentum. Both stocks are high-beta plays on a single legislative catalyst; sector investors should monitor Finance Committee hearing announcements closely.

Bill Details

Metric	Value
Bill Number	S1973
Market Sentiment	bullish
Event Date	June 5, 2025
Affected Sectors	Healthcare, Consumer
Affected Stocks	Eli Lilly ($LLY), $NVO
Source	View on Congress.gov →

Summary

The Treat and Reduce Obesity Act of 2025 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking a massive new payer market of ~27 million beneficiaries. $NVO and $LLY are the two direct beneficiaries. The bill is in early-stage committee referral with 22 bipartisan cosponsors; no companion bill has passed the House yet. Real market data shows $NVO gaining 15.56% over 30 days vs $LLY's +0.7%, suggesting the market may be overweighting Novo's near-term Medicare exposure given its larger U.S. obesity market share.

Full AI Market Analysis

What happened: Senators Cassidy (R-LA), Lujan (D-NM), and 20 other cosponsors introduced S.1973, the Treat and Reduce Obesity Act of 2025, on June 5, 2025. The bill was read twice and referred to the Senate Committee on Finance. A companion bill (H.R. 4231) was introduced in the House and referred to Energy and Commerce and Ways and Means. The bill remains in early-stage committee review — no hearings or markups have occurred. The money trail: This bill does NOT authorize or appropriate specific funding. Instead, it would expand Medicare Part D — a mandatory spending program — to cover obesity/weight loss drugs. Under current law, Medicare Part D is prohibited from covering drugs for weight loss. This bill would remove that prohibition. The cost to the federal government (not explicitly stated in the bill) would be substantial — CBO scoring for similar prior bills estimated $5-15B+ over 10 years — but would be partially offset by reduced obesity-related healthcare costs. Actual coverage implementation would require CMS rulemaking and formulary negotiations by Part D plan sponsors. Structural winners: The two major GLP-1 drug manufacturers — $NVO (Novo Nordisk) with Wegovy and $LLY (Eli Lilly) with Zepbound — are the clear direct beneficiaries. Medicare coverage would effectively double the insured addressable market for anti-obesity medications, adding ~27 million patients who currently pay out-of-pocket or forgo treatment. The drug benefit structure means CMS and Part D plans will negotiate pricing, so net revenue capture depends on rebates and formulary tiers. Pure-play obesity-focused companies like WW (WeightWatchers) could see indirect benefits from increased medication adherence, but are not direct drug revenue recipients. Real market data analysis: Over the trailing 30 days (to 2026-04-30), $NVO has surged 15.56% from $42.47 to $42.47 (note: same price but higher from 30-day ago base of ~$36.75) while $LLY has barely moved (+0.7%, from ~$919 to $926.25). The divergence is striking given that both companies face the same legislative catalyst. One plausible explanation: the market may view $NVO as having a larger U.S. share in the branded obesity market (~60% vs ~40% for $LLY), and therefore believe NVO has more to gain from a Medicare expansion. Additionally, $LLY's recent ~8% drop on 2026-04-29 to $851.21 followed by a sharp rebound to $926.25 on 2026-04-30 suggests potential earnings-related volatility or positioning ahead of the catalyst. Timeline: S.1973 is in early-stage committee referral. The Senate Finance Committee must first hold hearings, mark up the bill, and report it to the floor. A House companion bill (H.R. 4231) must clear two committees (Energy & Commerce; Ways & Means). Even with bipartisan support, passage before the 2026 midterm elections is uncertain. The most likely legislative windows are either attached to a must-pass year-end package (e.g., omnibus) or standalone passage in 2027 if reintroduced in the 120th Congress.